益心舒胶囊治疗冠心病心绞痛有效性及安全性的Meta分析  

Efficacy and Safety of Yixinshu(益心舒)Capsule in Treatment of Angina Pectoris in Coronary Heart Disease:A Meta-Analysis

作　　者：张晓刚[1] 赵信科[1,2] 刘凯 蒋虎刚[1] 王新强 赵晓彬 李倩蓉 李应东 ZHANG Xiaogang;ZHAO Xinke;LIU Kai;JIANG Hugang;WANG Xinqiang;ZHAO Xiaobin;LI Qianrong;LI Yingdong(Gansu University of Chinese Medicine,Lanzhou 730000;Affiliated Hospital of Gansu University of Chinese Medicine,Lanzhou 730020)

机构地区：[1]甘肃中医药大学,兰州730000 [2]甘肃中医药大学附属医院,兰州730020

出　　处：《中药药理与临床》2024年第5期75-81,共7页Pharmacology and Clinics of Chinese Materia Medica

基　　金：甘肃省中医药循证能力建设项目(编号:2019XZZX-XXG002);甘肃省科技重大专项计划(编号:20ZD7FA002)。

摘　　要：目的:系统评价益心舒胶囊联合常规西药治疗冠心病心绞痛的疗效和安全性。方法:检索相关数据库从建立以来到2021年12月收录的有关益心舒胶囊联合常规西药治疗冠心病心绞痛的临床随机对照试验(RCTs),根据纳入和排除标准选择益心舒胶囊联合西药治疗冠心病心绞痛的RCTs,并使用Review Manager 5.3软件进行Meta分析。结果:共纳入22项RCTs,总共3238名患者,Meta分析结果显示,益心舒胶囊联合常规西药能有效提高临床疗效[RR=1.20,95%CI(1.15,1.25)]、降低心绞痛的发生频率[MD=-1.56,95%CI(-2.42,-0.70)]、减少心绞痛持续时间[MD=-1.26,95%CI(-1.87,-0.65)]、提高心电图疗效[RR=1.19,95%CI(1.10,1.29)]、改善临床症状(1)胸痛[RR=1.15,95%CI(1.07,1.24)]、(2)胸闷[RR=2.52,95%CI(1.58,4.02)]、(3)心悸[RR=1.30,95%CI(1.19,1.41)]、(4)乏力[RR=1.42,95%CI(1.19,1.69)]、(5)气短[RR=1.35,95%CI(1.26,1.44)]、改善心率[MD=-3.66,95%CI(-6.61,-0.71)]、改善收缩压[MD=-4.60,95%CI(-9.55,0.35)]、改善舒张压[MD=-1.14,95%CI(-2.43,0.14)]、调节血清总胆固醇(TC)[MD=-0.87,95%CI(-1.46,-0.28)],调节三酰甘油(TG)[MD=-0.19,95%CI(-0.41,0.02)],增加高密度脂蛋白(HDL-C)[MD=0.31,95%CI(0.25,0.37)],降低低密度脂蛋白(LDL-C)[MD=-0.71,95%CI(-1.09,-0.34)]。试验组和对照组之间的不良反应发生率没有显著差异。结论:益心舒胶囊联合常规西药治疗冠心病心绞痛具有一定的临床疗效,值得广大医师临床验证。Objective:To systematically evaluate the efficacy and safety of Yixinshu(益心舒)Capsule combined with conventional western medicine in the treatment of angina pectoris in coronary heart disease.Methods:Databases such as China National Knowledge Infrastructure(CNKI),Wanfang Data,VIP,SinoMed,PubMed,Web of Science and The Cochrane Library were retrieved from the inception to December 2021.And the clinical randomized controlled trials(RCTs)of Yixinshu Capsule combined with conventional western medicine in the treatment of angina pectoris in coronary heart disease were included according to the inclusion and exclusion criteria.Meta-analysis was performed using Review Manager 5.3.Results:A total of 22 RCTs were included,involving 3238 patients.The Meta-analysis showed that Yixinshu Capsule combined with conventional western medicine exhibited effects in the following aspects:improving the clinical efficacy[RR=1.20,95%CI(1.15,1.25)],reducing the frequency of angina pectoris[MD=-1.56,95%CI(-2.42,-0.70)],shortening the duration of angina pectoris[MD=-1.26,95%CI(-1.87,-0.65)],enhancing the efficacy of electrocardiogram[RR=1.19,95%CI(1.10,1.29)],relieving the clinical symptoms[including chest pain[RR=1.15,95%CI(1.07,1.24)],chest tightness[RR=2.52,95%CI(1.58,4.02)],palpitation[RR=1.30,95%CI(1.19,1.41)],weakness[RR=1.42,95%CI(1.19,1.69)],and shortness of breath[RR=1.35,95%CI(1.26,1.44)]],improving heart rate[MD=-3.66,95%CI(-6.61,-0.71)],systolic blood pressure[MD=-4.60,95%CI(-9.55,0.35)]and diastolic blood pressure[MD=-1.14,95%CI(-2.43,0.14)],regulating serum total cholesterol(TC)[MD=-0.87,95%CI(-1.46,-0.28)]and triacylglycerol(TG)[MD=-0.19,95%CI(-0.41,0.02)],increasing high-density lipoprotein cholesterol(HDL-C)[MD=0.31,95%CI(0.25,0.37)],and decreasing low-density lipoprotein cholesterol(LDL-C)[MD=-0.71,95%CI(-1.09,-0.34)].There was no significant difference in the incidence of adverse reactions between the experimental group and the control group.Conclusion:Yixinshu Capsule combined with conventional western medicine has

关 键 词：益心舒胶囊 冠心病 心绞痛 META分析 

分 类 号：R259[医药卫生—中西医结合]